|Awarded On||February 21, 2019|
|Title||Targeting Hypomethylating Resistance in Myelodysplastic Syndromes|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Simona Colla|
*Pending contract negotiation
MDS patients who are treated with hypomethylating agents (HMAs, the current standard of care for this disease) almost universally develop resistance to these drugs and subsequently progress to acute myeloid leukemia. Patients in whom the therapy has failed have dismal prognoses and poor complete response rates to standard therapy. Almost nothing is known about the mechanisms underlying HMA resistance. To dissect the cellular and molecular mechanisms of HMA resistance we have analyzed 204 BM samples from MDS patients at different stages of the disease who were enrolled in clinical trials of HMA therapy. Our preliminary studies revealed that MDS can be further divided in two distinct biologic...